The use of amino acid PET and conventional MRI for monitoring of brain tumor therapy

Norbert Galldiks, Ian Law, Whitney B Pope, Javier Arbizu, Karl-Josef Langen

100 Citationer (Scopus)

Abstract

Routine diagnostics and treatment monitoring of brain tumors is usually based on contrast-enhanced MRI. However, the capacity of conventional MRI to differentiate tumor tissue from posttherapeutic effects following neurosurgical resection, chemoradiation, alkylating chemotherapy, radiosurgery, and/or immunotherapy may be limited. Metabolic imaging using PET can provide relevant additional information on tumor metabolism, which allows for more accurate diagnostics especially in clinically equivocal situations. This review article focuses predominantly on the amino acid PET tracers11C-methyl-l-methionine (MET),O-(2-[18F]fluoroethyl)-l-tyrosine (FET) and 3,4-dihydroxy-6-[18F]-fluoro-l-phenylalanine (FDOPA) and summarizes investigations regarding monitoring of brain tumor therapy.

OriginalsprogEngelsk
TidsskriftNeuroImage. Clinical
Vol/bind13
Sider (fra-til)386-394
Antal sider9
ISSN2213-1582
DOI
StatusUdgivet - 2017

Fingeraftryk

Dyk ned i forskningsemnerne om 'The use of amino acid PET and conventional MRI for monitoring of brain tumor therapy'. Sammen danner de et unikt fingeraftryk.

Citationsformater